Evidence map›Paper›PMID 38994535›Full record

ArticleBladder cancer (Amsterdam, Netherlands)2021

Spectrum of

Petros Grivas, Lesli A Kiedrowski, Guru P Sonpavde, Sumati V Gupta, Roby A Thomas, Theodore S Gourdin, Aaron I Hardin, Kimberly M Hamann, Bishoy M Faltas, Nicholas J Vogelzang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bladder cancer (Amsterdam, Netherlands), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Petros GrivasUniversity of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA, USA.
Lesli A KiedrowskiMedical Affairs, Guardant Health, Redwood City, CA, USA.
Guru P SonpavdeDana-Farber Cancer Institute, Boston, MA, USA.
Sumati V GuptaHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Roby A ThomasDivision of Hematology/Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Theodore S GourdinDivision of Hematology-Oncology, Medical University of South Carolina, Charleston, SC, USA.
Aaron I HardinMedical Affairs, Guardant Health, Redwood City, CA, USA.
Kimberly M HamannMedical Affairs, Guardant Health, Redwood City, CA, USA.
Bishoy M FaltasDivision of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA.
Nicholas J VogelzangUS Oncology Research, Comprehensive Cancer Centers of Nevada, University of Nevada, Las Vegas, NV, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Detecting genomic alterations (GAs) in advanced urothelial carcinoma (aUC) can expand treatment options by identifying candidates for targeted therapies. Erdafitinib is FDA-approved for patients with platinum-refractory aUC with activating mutation or fusion in

Identifiers

PMID38994535
PMCPMC11181711

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.